Kornimate/medical-research-clean huggingface dataset:
covid-19 in patients with hiv

Conditions: HIV/AIDS; COVID-19; SARS-CoV-2

Summary: currently, limited data is available about patients with hiv in the context of the covid-19 pandemic. people with hiv who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. however, little is known about the presentation and clinical outcomes of patients with hiv and sars-cov-2. our aim is to characterize the clinical presentation and disease course of covid-19 in patients with hiv.

currently, limited data is available about patients with hiv in the context of the covid-19 pandemic. people with hiv (pwh)/aids, or people with hiv who have not achieved viral suppression through antiretroviral treatment may have at higher risk for sars-cov-2 infections and disease progression. at present there is no evidence to suggest that there is an increased risk of infection and increased severity of illness for pwh. we know that during the sars and mers outbreaks, there were only few case reports of mild disease among pwh. current clinical data suggest the main mortality risk factors are linked to older age and other co-morbidities. however, some healthy people have also developed severe disease from the sars-cov-2 infection. this is a multi-center prospective observational study. our aim is to characterize the clinical presentation and clinical course of covid-19 in patients with hiv. patients with hiv and confirmed sars-cov-2 will be identified during routine clinical care in the inpatient or outpatient setting. contributors will share de-identified demographic data, health history data, and clinical data pertaining the patient's presentation with covid-19 and outcomes obtained during routine care for their patients, using the secure online data collection tool redcap.

Eligibility criteria:
inclusion criteria: * hiv disease * laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay exclusion criteria: * none

Keywords: hiv aids covid-19 sars-cov-2 clinical presentation progression clinical outcome
evaluation of patients' knowledge of their vaccination status and their relationship to vaccination at melun hospital

Conditions: Vaccinia

Summary: the goal of this observational study is to learn about the rate of knowledge of own vaccination status among patients hospitalized at melun hospital. the main questions it aims to answer are: * the rate of knowledge of its vaccination status among patients hospitalized at melun hospital * hospitalized patients' attitude to vaccination in general. evaluate the number of patients wishing to update their vaccination status. observe the influence of various factors (gender, occupation, presence or absence of gp, chronic illness) on vaccination status in melun, france participants will be asked to complete a questionnaire during hospitalization.

as part of the national "european vaccination week" event organized by the french ministry of health and prevention, we are asking a sample of patients hospitalized in our hospital to complete a questionnaire on their knowledge of their vaccination status, and to assess their relationship with vaccination. questionnaire administered to patient during hospitalization (n=140 patients). patients randomly selected by the department of medical information of the hospital at the beginning of the survey week. patients randomly selected from each of the 10 departments of the ch of melun (internal medicine, infectious diseases, gastroenterology, pneumology, surgery, bcr medicine, cardiology, nephrology, follow-up care and rehabilitation and geriatrics) and accompanied to complete a questionnaire set up by the public health unit (usp) and hygiene operational team (eoh) of the ch of melun.

Eligibility criteria:
inclusion criteria : * french-speaking and non-demented patient : able to speak and understand french and without dementia * adult patient (age ≥ 18 years) * main place of residence in france * hospitalized in a department of the ch of melun exclusion criteria : * does not speak french or dementia * patient's refusal to participate in the study
a study to assess selected biomarkers in subjects requiring daily inhaled corticosteroids for persistent asthma

Conditions: Asthma

Summary: the rationale for conducting this study is to explore potential clinical and peripheral biomarkers in subjects requiring daily medium to high dose inhaled corticosteroids for persistent asthma


Eligibility criteria:
inclusion criteria: * age 18 through 75 at the time of screening * written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations * history of physician-diagnosed asthma for at least 12 months prior to screening * stable medium- to high-dose ics divided twice daily as outlined by the nhlbi asthma guidelines, 2007 exclusion criteria: * any medical condition that, in the opinion of the investigator or medical monitor, would interfere with interpretation of subject safety or study results * concurrent enrollment in another clinical study * use of immunosuppressive medication within 3 months prior to screening * acute upper or lower respiratory infections requiring antibiotics or antiviral medications with in 30 days prior to screening or during screning period. * receipt of immunoglobulin or blood products within 30 days prior to screening or during the screening period * receipt of any investigational non-biological drug therapy within 30 days or 5 half-lives prior to screening whichever is longer; or receipt of any marketed or investigational biologic within 6 months or 5 half-lives prior to screening whichever is longer * pregnant, lactating, or breastfeeding woman * diagnosis of lung disease other than persistent asthma * history of smoking ≥10 pack years or any smoking within 12 months prior to screening * history of active, infectious hepatitis a, b, c or human immunodeficiency virus (hiv)
bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers

Conditions: Gastrointestinal Tract Infections; Respiratory Tract Infections

Summary: hypothesis: use of bifidobacterium animalis subsp. lactis can effectively prevent common infections (gastrointestinal and respiratory) in healthy children who attend day care centre this study is a prospective, randomized, double blind, placebo- controlled parallel study in healthy children attending day care centers. the study will investigate the effect of supplementation with the probiotic strain bifidobacterium animalis subsp. lactis on the incidence and duration of gastrointestinal and respiratory infections and absence from day care due to infections. the test product is a sachet containing 1 gram of powder. the test product will contain minimum 1 billion cfu (colony forming units) of probiotic per serving. the placebo product is an identical product except for the absence of probiotics. the study includes 3 months (90 days) of intervention period. the study product will be consumed daily in the evening together with a meal. the consumption of the study products will be taken under the surveillance of the parents. during the entire intervention period the subjects are not allowed to consume any probiotic products other than the study products supplied to them by the study personnel. data on infections will be recorded in a diary, filled in and administered by the parents and diary recorded by referring physician (on-call log). all infections are to be diagnosed by the local physician. the incidence of infections will be analyzed based on the information recorded in the diaries (parent's \& physician's).


Eligibility criteria:
inclusion criteria: * healthy children attending day care at kindergartens located in the zagreb's city centre * age from 1 year to 7 years * attendance at daycare centers: \> 3 days per week * signed informed consent by the parents exclusion criteria: * immunodeficiency * receiving probiotic and /or prebiotic products prior to enrolment (2 weeks prior to study start) * neoplasms * severe chronic disorders
intrastromal corneal ring for ectasia after refractive surgery (anel)

Conditions: Ectasia

Summary: to evaluate the clinical outcomes of intrastromal corneal ring segment (icrs) implantation to correct keratoconus on eyes with prior refractive surgery.

forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series. mean age at the time of icrs implantation was 30,5 years.

Eligibility criteria:
inclusion criteria: * patients 19 to 48 years old * keratoconus (ectasia) on eyes with prior refractive surgery exclusion criteria: * diabetes * autoimmune diseases

Keywords: intrastromal corneal ring astigmatism
glycemic response to momordica charantia in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: diabetes is a common disease which has been treated by traditional medicines for centuries before modern medicine became available. a very common remedy for diabetes mellitus in different cultures is momordica charantia (karela or bitter gourd). the use of alternative medicine is common among pakistani population. this study was planned to find out the effect of administering freeze dried powder of momordica charantia for three weeks on the glycemic profile and insulin resistance of treatment naiive patients with mild type 2 diabetes.

momordica charantia is a commonly consumed vegetable, which has formed a part of subcontinental diet since centuries. it has been traditionally used to treat diabetes across three continents, and its glycemic effect has been investigated in a few unblinded trials, but so far no properly designed double blind investigation of its action on insulin resistance has not been carried out. in this study, a randomised placebo controlled double-blind trial will be carried out on mild type 2 diabetic patients, to study the effect of escalating doses of momordica charantia administered in the form of capsules for the trial phase of three weeks, on glycemic control and parameters of insulin resistance in type 2 diabetes. among the parameters to be tested will be glucose indices and lipid profile and insulin levels. the effect of momordica charantia administration on insulin resistance will be assessed using homa-ir model and/ or the hyperinsulinemic, euglycemic clamp. the selection of patients with mild hyperglycemia will be done to offset the glucose spill-off effect which occurs beyond the real threshold, and makes the glucose tolerance curve non-linear beyond this level.

Eligibility criteria:
inclusion criteria: 1. adult type 2 diabetics with mild degree of hyperglycemia (fbg \>126\<200 mg/dl) 2. absence of serious co-morbid conditions 3. patients agreeing to participate in this trial exclusion criteria: 1. type 1 diabetics 2. pregnancy 3. paediatric age group 4. patients known to be allergic to momordica charantia 5. serious cardio-respiratory illness, previous myocardial infarction, angina pectoris, heart failure, uncontrolled hypertension ≥ stage 2, copd, asthma, active pulmonary tuberculosis 6. significant hepatic impairment: alt \>60, bilirubin \>2 mg/dl 7. significant renal impairment: s/creatinine \>1.5 mg/dl, albuminuria \> 1+ 8. patients with conditions likely to interfere with the absorption of the trial therapy: malabsorption, chronic diarrhoea, intestinal resection, blind loop syndrome 9. patients withholding consent 10. patients, both male and female, desiring pregnancy during the trial phase. 11. secondary causes of diabetes 12. patients using drugs influencing glucose metabolism: steroids, hormonal contraception, menopausal hrt , diazoxide, phenytoin, colchicine

Keywords: diabetes type 2
relative effects and predictive models of contemporary upper limb training programs in stroke patients

Conditions: Cerebrovascular Accidents

Summary: the findings of this study will advance movement reorganization mechanism underlying treatment approaches and clinical intervention techniques. these findings may inform rehabilitation professionals about which treatment approach is superior to another one in certain aspect of outcome and who can benefit most from certain treatment approach. accordingly, the results of this project may help us move quickly to design and develop efficient and effective rehabilitation programs for individualized patients.

the first purpose is to investigate the relative effects of modified constraint-induced therapy (mcit) vs. bilateral isokinematic training (bit) vs. traditional or therapist-based training (tr) on movement reorganization, motor performance, functional ability, and quality of life (qol) immediately and six months later after treatment delivered at hospitals. movement reorganization will be evaluated by kinematic instrument. motor performance, functional ability, and qol will be assessed using clinical assessment tools. by the same token, we also investigate the relative effects of these two approaches delivered at home. the second purpose is to study whether home-based mcit is efficacious in various aspects of outcomes described above immediately and six months later following treatment, compared to home-based tr, and hospital-based mcit and tr.we also study the same question regarding home-based bit efficacy. the third purpose is to establish predictive models to predict functional and qol outcomes immediately and six months later following mcit and bit.

Eligibility criteria:
inclusion criteria: * the onset duration more than 6 months * brunnstrom stage iii above for the proximal part and distal part of ul * no serious cognitive deficits * no balance problems sufficient to compromise safety when wearing the project's constraint device * no excessive spasticity in any of the joints of the affected ul exclusion criteria: * a score of less than 24 on the mini mental state exam

Keywords: stroke rehabilitation kinematic analysis upper extremity training predictors
dosimetric validation of scans generated by gan from pre-therapeutic mri in stereotactic cerebral radiotherapy

Conditions: Brain Metastases

Summary: stereotactic radiotherapy (srt) is being widely accepted as a treatment of choice for patients with a small number of brain metastases and an acceptable size, allowing a better target dose conformity resulting in high local control rates and better sparing of organs at risk. currently, imaging for such a delivery technique requires both a recent magnetic resonance imaging (mri) brain study for volume definition and a computed tomography (ct) scan for srt planning. an mri-only workflow could reduce the risk of misalignment between the two imaging modalities and shorten the delay of planning. given the absence of a calibrated electronic density on mri, the investigators aim to assess the equivalence of synthetic cts generated by a generative adversarial network (gan) for planning in the brain srt setting.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * srt treatment for one or more brain metastasis(ses) * brain mri and planning ct scans realized less than 14 days prior to the treatment delivery exclusion criteria: * mri's field of view (fov) judged insufficient for tumour(s) and oar visualization
the heartspare plus 1b trial

Conditions: Breast Cancer

Summary: this study aims to compare the resource impact, acute toxicity and feasibility of different pan-lymph node radiotherapy techniques. radiotherapy using wide tangents with the patient in breath hold will be compared against volumetric modulated arc therapy (vmat) in free breathing in the main trial. a parallel study will asses the accuracy of vmat treatments using voluntary deep inspiratory breath hold compared to an active breathing controlled breath hold device.

following publication of results of two large randomised clinical trials, pan-lymph node radiotherapy (pan-ln rt) (including treatment of the internal mammary chain) is set to become standard treatment in patients with lymph-node positive breast cancer. traditional pan-ln rt techniques deliver high radiation doses to the heart and lungs which can cause long-term side-effects in women many years after their treatment. modern techniques including breath-holding and volumetric-modulated arc therapy (vmat) can reduce doses to heart and lungs but the investigators do not yet know which technique(s) are best in terms of resource costs, short to medium-term side-effects, and day to day accuracy. this study will compare the time taken to deliver pan-ln rt using breath-holding versus vmat and will collect side-effect data up to one year following treatment as well as modelling long-term cardiac risks based on heart doses delivered. the results of the main study will help guide clinicians and departments in selecting the best pan-ln rt techniques for their patients. a parallel study will evaluate the combination of breath-hold and vmat using a machine-based technique called the active-breathing controlled (abc) device against a more simple voluntary breath-hold technique were patients simply take a breath in and hold it for up to 20 seconds at a time. these techniques will be compared in terms of their day-to-day accuracy. if the simpler technique proves as accurate as the abc-technique, this will establish the simpler technique as a less resource-intensive standard of care adoptable by other radiotherapy departments.

Eligibility criteria:
inclusion criteria: * age ≥18 years * female or male * invasive carcinoma of the breast (left or right-sided) * breast conservation surgery or mastectomy * axillary staging and/or dissection * pt1-t4,n1-2,m0 disease * histological involvement of axillary lymph nodes * indication for radiotherapy to the imc, axillary levels i-iii and/or level iv * patient able to tolerate breath hold * performance status 0-1 exclusion criteria: * contralateral and/or previous ipsilateral breast cancer, irrespective of date of diagnosis * past medical history of malignancy except (i) basal cell skin carcinoma, (ii) cin cervix uteri, (iii) non-breast malignancy allowed if treated with curative intent and at least 5 years disease free * previous radiotherapy to any region above the diaphragm
surgical management of complex intracranial aneurysms with hybrid operating techniques

Conditions: Intracranial Aneurysm

Summary: to evaluate the clinical benefits and risks of hybrid operating techniques in management of complex intracranial aneurysms, which could coexists with multiple risk factors.

purpose: have an evaluation of clinical benefits and risks of hybrid operating techniques in management of complex intracranial aneurysms (cias), which could coexists with multiple risk factors. meanwhile, as a new cooperative interventional modality, optimized workflows, technical key knots and operation routines will be explored in the study. objects: patients with cias, coincident with inclusion and exclusion criterion and admitted in participating organizations. methods: patients will be distributed into 2 groups, including traditional therapy group(control group) and hybrid operating group(trial group), and conduct with traditional neurosurgical management or one-stage hybrid operating management correspondingly. peri-operative mortality rate is considered to be the primary observing indicator, and morbidity rate of peri-operative cerebral hemorrhagic/ischemic event, morbidity rate of aneurysmal residuals, morbidity rate of neural functional deteriorations, and health-economic indicators are secondary indicators.the information of operations will be recorded in detail as evidence of optimization of workflow and technical key knots.

Eligibility criteria:
inclusion criteria: * with diagnosed complex intracranial aneurysm by digital subtraction angiography(dsa); * got sah in history; * neural functional deficits due to aneurysms; * with \<4 in hunt-hess grades; * ≥5.0mm in the maximum diameter; * \<70 years old; * with irregular morphological features and high rupture risk. exclusion criteria: * \>70 in age, with low rupture risk; * cannot tolerant the operation; * patient or relative refuses to participate the trail; * sah patient with ≥4 hunt-hess grading system; * \<5.0mm in the maximum diameter.
genetic analysis of keloids

Conditions: Keloid

Summary: keloids have a strong genetic component. the goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for keloids or contribute to keloid scarring.

keloids are scars that keep growing beyond the border of the original wound. they typically persist for several years, expand for an extensive period of time and are sometimes called benign tumors. keloids often have a lumpy surface and are often tender, itchy or inflamed around the growing border. keloids in most keloid patients do not run in the family. in the inheritable form of keloids it is possible that there is one major gene mutation that puts family members at risk for developing keloids. there may be other variations in the dna (dna makes up the chromosomes) that determine whether keloids become large and aggressive or stay small and without many symptoms. for this study we will: * send out study participation kits and consent by phone * collect a saliva sample from eligible individuals * obtain information regarding the keloids * document keloids with photos * if keloid patients undergo keloid surgery we ask to obtain some scar tissue that would otherwise be discarded * isolate dna from the saliva sample * perform genetic analyses of the dna with the most up-to-date methods available to identify genetic variations * study in the laboratory why the genetic variations cause keloids

Eligibility criteria:
inclusion criteria: * keloids; * unaffected individuals only if part of a participating keloid family exclusion criteria: * no keloids; * unaffected individuals only as part of a participating keloid family

Keywords: keloid fibrosis wound healing scar